The new joint guidelines from the ADA-EASD and the EAS put emphasis on personalizing the choice of the preferential use of molecules from the GLP1-RA and SGLT2-i classes. They have demonstrated cardio-renal benefits beyond their hypoglycemic and weight-lowering effects in Type 2 diabetes (T2DM) patients with proven cardiovascular (CV) damage or high cardio-renal risk. For insulin treated T2DM patients who have benefited from continuous interstitial glucose measurement, reimbursed since 2023, well-defined glucometric targets have been proposed in addition to the usual HbA1c measurement. In addition, the 10-year CV risk can be assessed in T2DM patients undergoing primary cardio-renal prevention, using the recently introduced European SCORE2-Diabetes calculator.
Keywords
Guidelines; Type 2 diabetes; residual risk; CGM; cardiorenal; SCORE2-Diabetes